<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597153</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-HE154/PRO/Ⅱ</org_study_id>
    <nct_id>NCT02597153</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas</brief_title>
  <official_title>A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Cutaneous T Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with relapsed
      cutaneous T cell lymphomasell
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Just one subject enrolled in this trial during one and a half years.
  </why_stopped>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR; complete response + partial response [CR + PR])</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Time from the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented (assessed up to approximately 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR (assessed up to approximately 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to a total of 24 months after first dose or until disease progression, withdrawal from study, or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus remission rate</measure>
    <time_frame>Up to a total of 24 months after first dose or until disease progression, withdrawal from study, or death</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Relapsed Cutaneous T Cell Lymphom</condition>
  <arm_group>
    <arm_group_label>Mitoxantrone HCL Liposome Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment cycle lasts for 28 days with 20mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone HCL Liposome Injection</intervention_name>
    <arm_group_label>Mitoxantrone HCL Liposome Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects are voluntary and sign the informed consent form;

          -  ECOG score 0 to 2;

          -  The expected survival time ≥3 months;

          -  Patients with cutaneous T-cell lymphoma confirmed by histopathology, with measurable
             lesions, with or without systemic lymph node involvement; clinical stage IB-IVA;

          -  The patients previously receive at least once of systemic therapy (including systemic
             electron beam irradiation or chemotherapy, stem cell transplantation) and do not
             achieve remission (including remission period shorter than 30 days after the
             treatment;

          -  An interval of at least four weeks after the target tumor was treated with
             chemotherapy, radiotherapy, biological therapy, stem cell transplantation or other
             study drugs;

          -  Subjects at childbearing age agree to take effective contraceptive measures during the
             study; blood pregnancy test result is negative (except infertility due to menopause or
             operation);

          -  Laboratory tests (blood routine, liver and kidney function) meet the following
             requirements:

               1. ANC≥ 1.5×109/L; b) PLT ≥ 75×109/L; c) Hb ≥ 9 g/dL; d) Cr) ≤ 1.5x ULN ; e) TBIL ≤
                  1.5x ULN; f) AST or ALT ≤2.5 x ULN.

        Exclusion Criteria:

          -  Pregnant or lactating women;

          -  An allergic history to anthracyclines or liposome drugs;

          -  Disease progression or recurrence after anthracycline treatment within six months
             before the enrollment;&quot;

          -  Patients who once used mitoxantrone injection;

          -  Patients who have used doxorubicin (or pirarubicin) with the total cumulative dose&gt;
             360mg/m2, or epirubicin with the total cumulative dose &gt; 600mg/m2;

          -  Left ventricular ejection fraction is &lt; 50% or &lt; the lower limit of normal; clinically
             significant QT interval prolongation (&gt;450ms in male, &gt;470ms in female); a past
             history of cardiac disease caused by anthracyclines; a history of severe heart
             disease;

          -  Concomitant treatment as other anticancer drugs are needed;

          -  With internal organ involvement (including bone marrow, central nervous system;

          -  Clinically active infection that can significantly affect the clinical trial;

          -  Within 6 weeks after organ transplantation or major organ surgery;

          -  Those who are inappropriate to be enrolled as evaluated by the researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

